Physician profile
David J Rodman
NPI 1548254840
$5,260.12
in general payments reported to CMS, 2019-2025
17 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,127 · 2020: $39.54 · 2021: $526 · 2022: $957 · 2023: $1,255 · 2024: $891 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,489 · Consulting Fee: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,489.35 |
| Consulting Fee | $120.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,684.12 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $462.08 | 2022-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $387.39 | 2023-2025 | Syfovre |
| Bausch & Lomb Americas INC. | $376.02 | 2022-2024 | Miebo, Vyzulta, Xiidra |
| Aerie Pharmaceuticals, INC. | $350.61 | 2019-2021 | |
| Horizon Therapeutics Plc | $332.02 | 2022-2023 | Tepezza |
| Allergan, INC. | $319.47 | 2019-2022 | |
| Alcon Vision LLC | $314.35 | 2021-2025 | Rocklatan, Eysuvis |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $292.93 | 2019-2021 | |
| Alimera Sciences, INC. | $179.18 | 2020-2022 | |
| Oyster Point Pharma, INC. | $139.78 | 2022 | |
| Genzyme Corporation | $120.96 | 2023 | |
| Novartis Pharmaceuticals Corporation | $104.93 | 2019 | |
| Abbvie INC. | $71.70 | 2022-2025 | |
| Amgen INC. | $59.07 | 2025 | Pavblu |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $50.72 | 2019-2023 | Cequa |
| Eyevance Pharmaceuticals LLC | $14.79 | 2023 | Flarex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.